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Pyoderma gangrenosum (PG) is an uncommon
neutrophilic dermatosis characterized classically by
the development of rapidly expanding painful ul-
cerations often on the lower extremities. Although
most commonly associatedwith inflammatory bowel
disease, acute leukemia, myelodysplastic syndrome,
or monoclonal gammopathy, PG has been reported
in association with systemic lupus erythematosus,
autoimmune hepatitis, relapsing polychondritis, and
sarcoidosis.1Fig 1. A 13- 3 9-cm ulcer with pseudovesicular borders
on patient’s right medial portion of the lower leg.CASE REPORT
A 59-year-old woman with tumor stage cutaneous
T-cell lymphoma (CTCL) presented with fevers and
leg ulcers. She was recently discharged from the
hospital for aseptic thrombophlebitis of her right
upper extremity treated with vancomycin and cefe-
pime for 7 days.
The patient had CTCL diagnosed in 2000 when
she presented with patches on her thighs. Peri-
pheral flow cytometry results were normal, but she
had a positive clonal T-cell receptor gene rearrange-
ment. Her early treatments, including topical ste-
roids, photochemotherapy, and acitretin, only
briefly controlled her disease. Subsequently she
received numerous systemic agents including
methotrexate, bexarotene, romidepsin, denileukin
diftitox, and vorinostat; 6 cycles of etoposide,
prednisone, vincristine, cyclophosphamide, and
doxorubicin (EPOCH) chemotherapy; total body
electron beam radiation; and an autologous stem
cell transplant. Her disease was finally controlled
with gemcitabine infusions twice a week eventually
tapered to every other week until her current
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486@cumc.columbia.edu.On physical examination, 2 annular ulcerative
plaques with pseudovesicular borders each
measuring 4 3 4 cm were noted on the patient’s
left medial calf. Her right medial calf had a much
larger severely painful rapidly enlarging ulceration
with pseudovesicular borders measuring 13 3 9 cm
at its widest borders (Fig 1). Both leg ulcers were not
present on her previous discharge 7 days before.
Two 4-mm punch biopsy sections were obtained
from the right medial portion of the lower leg
with half of each specimen sent for hematoxylin-
eosin staining and the other half sent for tissue
culture. Biopsy specimens showed a diffuse infiltrate
of neutrophils in the dermis extending to the subcu-
tis (Fig 2). Immunohistochemical stains showed noJAAD Case Reports 2015;1:93-5.
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Fig 2. Right medial portion of the lower leg punch biopsy. A, Dense dermal infiltrate of
neutrophils extending into the subcutis. B, High-power demonstrates diffuse infiltrate of
neutrophils. (A and B, Hematoxylin-eosin stain; original magnifications: A, 310; B, 340.)
Fig 3. Patient at 6-month follow-up. Minimal indurated
plaque after treatment with prednisone and minocycline.
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cultures for fungi, bacteria, and mycobacteria were
normal. Laboratory workup found a C-reactive pro-
tein level of 322 mg/L (reference range,\2.90 mg/L)
and an erythrocyte sedimentation rate of 75 mm/h
(reference range, 0e20 mm/h) as the only laboratory
abnormalities. The clinical and pathologic findings
were consistent with the diagnosis of pyoderma
gangrenosum.
DISCUSSION
There are no reports to date of PG occurring
concurrently in association with CTCL or CTCL
complicated by PG. Hussain et al2 reported an 83-
year-old man who had an ulcerative plaque with
undermined edges on the right upper thigh with a
skin biopsy consistent with pyoderma gangrenosum.
He was treated successfully with minocycline and
oral prednisone. Two months after cessation of
therapy, the patient had a widespread eruption
confirmed by skin biopsy as CTCL.2 Additionally,
there have been rare reports of CTCL presenting as
PG-like lesions.3-5
Our patient with PG in the course of her CTCL
was treated initially with prednisone at 1 mg/kg.
When no response was noted after 2 days, mino-
cycline, 100 mg twice a day, was added. Her lesions
stopped progressing, and she reported significant
reduction in pain after 4 days of treatment. She was
discharged on hospital day 15 and continued
taking minocycline twice daily for 2 months.
Prednisone was tapered over a course of 5 months.
At 6 months, her lesions were all healed with
postinflammatory hyperpigmentation or minimal
indurated dyschromia (Fig 3). Unfortunately, the
patient had disease progression with rapid increase
in number of tumors all over her body with several
becoming ulcerated, painful, and superinfected.She declined further treatment and ultimately
opted for hospice care.
Association of PG with inflammatory disorders is
well established, suggesting that dysregulation of the
immune system plays a role in the disease patho-
genesis.6 Increased production of proinflammatory
cytokines such as interleukin (IL)-8, a very potent
neutrophil chemotactic factor, has been seen in PG7
and linked to ulcer formation. IL-8 is rarely found in
CTCL biopsies, but when it is elevated in the
epidermis of CTCL patients, it is always associated
with accumulation of neutrophils.8
CTCL is also considered a disease of immune
dysregulation with chronic antigenic stimulation
possibly playing a role in its pathogenesis. In
particular, CTCL has been linked to several infectious
agents that induce cells of the innate immune
response, including macrophages and keratinocytes
to secrete cytokines such as IL-8.9 Recently it was
shown that levels of IL-8 are significantly and
constitutively elevated in the serum of CTCL pa-
tients,10 suggesting for the first time that dysregula-
tion of innate immune responses may be important
in CTCL disease pathogenesis.
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toll-like receptors on keratinocytes and other innate
immune cells may lead to generation of a specific
immunologic profile in CTCL lesions with IL-8 over-
production directly in the tumor microenvironment.
In this case, continuous overproduction of IL-8 by
perhaps an infectious etiology could have led to
neutrophil accumulation and formation of PG. Our
hypothesis may also explain why our patient re-
spondedwell to antibiotics and not to steroid therapy.
In the patient with CTCL and new-onset enlarging
painful ulcerations, the differential diagnosis of
ulcerated CTCL, infection, and pyoderma gangreno-
sum has critical therapeutic importance for survival.
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